TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07843472: A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardi

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 2500 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07843472 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07843472 Rescue Dossier →